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In animal models, single-gene mutations in genes involved in insulin/IGF and target of rapamycin
signalling pathways extend lifespan to a considerable extent. The genetic, genomic and epigenetic
inﬂuences on human longevity are expected to be much more complex. Strikingly however, ben-
eﬁcial metabolic and cellular features of long-lived families resemble those in animals for whom
the lifespan is extended by applying genetic manipulation and, especially, dietary restriction. Can-
didate gene studies in humans support the notion that human orthologues from longevity genes
identiﬁed in lower species do contribute to longevity but that the inﬂuence of the genetic variants
involved is small. Here we discuss how an integration of novel study designs, labour-intensive bio-
banking, deep phenotyping and genomic research may provide insights into the mechanisms that
drive human longevity and healthy ageing, beyond the associations usually provided by molecular
and genetic epidemiology. Although prospective studies of humans from the cradle to the grave
have never been performed, it is feasible to extract life histories from different cohorts jointly cover-
ing the molecular changes that occur with age from early development all the way up to the age at
death. By the integration of research in different study cohorts, and with research in animal models,
biological research into human longevity is thus making considerable progress.
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1. INTRODUCTION
Genomic studies into human longevity are inspired by
the fact that, in animal models, healthy lifespan has
proved to be remarkably plastic, and major pathways
of lifespan regulation have been identiﬁed. Consider-
able lifespan extension has been induced in models
as diverse as yeast, worms, ﬁsh, ﬂies and rodents by
applying genetic manipulation and dietary restriction
(DR) (see [1] for review). Reduced activity of nutri-
ent-sensing pathways such as insulin/insulin-like
growth factor (IGF-1) signalling (IIS) and target of
rapamycin (TOR) signalling mediated lifespan exten-
sion, and also the extension of lifespan by DR [2].
An interesting observation from the perspective of
human ageing is that, in rodents and monkeys, diets
restricted in glucose, fat or protein uptake reduced or
delayed the risk of cancer and metabolic disease,
thus extending the healthspan of the animals [2]. Fol-
lowing the discovery of genes and pathways involved in
animal lifespan extension, human research has focused
on the corresponding candidate human genes with
genetic, genomic and epigenetic studies into ageing
and longevity. The designs of these studies differ
with respect to the selection of naturally occurring
phenotypes and the study populations, which include
population-based, patient-based, family-based and
exposure-based cohorts.
Studies into human age-related disease phenotypes
are focused on population-based and patient-based
cohorts of elderly individuals in order to ﬁnd mechan-
isms that contribute to the onset and/or progression of
complex common diseases. For all common diseases,
calendar age is a major risk factor and many disease-
related parameters, such as serum glucose level,
typically change as a function of age. Attempts are
being made to interpret which combination of age-
related parameters reﬂects the biological ageing rate
of individuals and which of these biomarkers of
ageing could inﬂuence the onset of disease and of
co-morbidity. Such molecular epidemiology studies
are combined with genomic approaches to identify
the biological mechanisms that may be causally
involved in the onset of morbidity and mortality.
These investigations require large study cohorts that
allow stratiﬁcations for age and sex with repeated con-
ﬁrmation of observations in independent studies and,
as we shall discuss here, cover research into life-history
changes from conception until death.
Developmental processes and early-life program-
ming may contribute to the onset of disease later
in life. Epidemiological studies have associated
characteristics of early development such as birth
weight with the occurrence of later disease [3].
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into the aetiology of osteoarthritis, a common joint
disease. A number of the genes identiﬁed for this dis-
ease are active in the growth plate and silenced in
adult life. Disease susceptibility variants are expected
to contribute early in life to mild skeletal malfor-
mations and later in life to affect homeostasis of
articular cartilage [4].
In addition to the late effects of developmental pro-
cesses, ageing is likely to be affected by longevity
assurance mechanisms. In the last decade, human
longevity studies have been initiated in cohorts of indi-
viduals and their family members to ﬁnd protective
mechanisms delaying the ageing-related phenotypes
and disease onset in highly and exceptionally aged
subjects.
2. DESIGNS TO STUDY PARAMETERS OF
HEALTHY AGEING, MORBIDITY, MORTALITY
AND LONGEVITY
Human cohorts may vary considerably in their mor-
bidity, mortality and longevity characteristics and yet
they have shown a common increase in mean life
expectancy in the past two centuries [5]. This is
mainly due to improved hygiene, nutrition and health-
care. There is a large variation in healthy lifespan
among the elderly and remarkably exceptional longev-
ity (EL) can be reached with a low degree of age-
related disability [6,7]. Heritability studies comparing
the concordance of lifespan in monozygous and dizy-
gous twins estimated a 25–30% genetic contribution
to human lifespan variation [8–11], which becomes
increasingly important at higher ages. The most pro-
minent genetic inﬂuence is present in families in
which survival to high ages clusters [12,13]. Unlike
model systems where single-gene mutations have
major life extension effects, human longevity is
presumed to be a complex trait [14].
The design of studies aimed at the extraction of
molecular parameters determining biological ageing
and longevity includes the cross-sectional designs
comparing unrelated humans in groups of different
calendar age. Such studies may also include follow-
up data that must be considered the more unbiased
design to associate biological parameters with morbid-
ity and mortality (Leiden 85 plus Study, Danish 1905
cohort). The cross-sectional design is especially
sensitive to differences in cohorts confounding the
associations one is aiming to observe. Controls from
the birth cohort of long-lived individuals are now
deceased, so younger controls originate by deﬁnition
from other birth cohorts than the long-lived individ-
uals. As a result of high mortality and changes in the
mortality rate at higher ages, a true observation of
how a parameter associates with survival in a popu-
lation can be obtained only by a combination of
prospective studies with increasing baseline ages.
To improve the design for genetic studies, families
enriched for familial longevity are being investigated.
These have been selected by either recruiting nona/
centenarians and their middle-aged offspring (the
Ashkenazi Jewish Centenarian Study) or nonagenarian
sibling pairs and their middle-aged offspring (Leiden
Longevity Study, Genetics of Healthy Ageing
(GEHA)/Mark-Age study). The offspring of long-
lived individuals representing (as a group) cases pre-
disposed to longevity can now be compared with
middle-aged controls (spouses) from the same geo-
graphical background and birth cohort to investigate
which age-related phenotypes actually associate with
familial longevity. Resembling the ability of a time
machine to observe what happened to a person years
ago, this study design allows the multi-generational
analysis of molecular and clinical parameters speciﬁc
for long-lived individuals and their family members
at elderly, middle and younger ages.
One of the studies on which we focus in this paper is
the Caucasian family-based Leiden Longevity Study
(LLS; ﬁgure 1) in which long-lived siblings were
recruited together with their offspring and the partners
thereof. Families were recruited if at least two long-
lived siblings were alive and fulﬁlled the age criterion
of 89 years or older for males and 91 year or older
for females, representing less than 0.5 per cent of the
Dutch population in 2001. In total, 944 long-lived
proband siblings were included with a mean age of
93 (89–103), 1671 offspring of a mean age of
59 (34–80) and 744 partners of a mean age of 59
(30–79).
The study design (ﬁgure 1) shows that, in cross-
sectional studies, phenotypes can be compared
between familial nonagenarians and sporadic elderly
from the population (such as from the Leiden 85
plus Study) to distinguish familial longevity markers
from parameters marking all long-lived individuals.
Parameters can also be compared between offspring
and partners (as controls sharing a signiﬁcant portion
of socio-economic environment) or, to avoid missing
associations owing to assortative mating, between off-
spring and other middle-aged controls from the
general population. The association analyses can also
be performed in the context of the survival history of
the family; in which case a longevity phenotype is
most prominent in families expressing the most
extended survival (by a combination of exceptional
ages at death and the number of family members
reaching such high ages). Convincing evidence for a
phenotype to be a marker of biological age is provided
if prospective studies show that baseline variation in
the phenotype associates with morbidity or mortality
in the time to follow-up (ﬁgure 1).
3. PHENOTYPES REFLECTING (UN)HEALTHY
AGEING AND FAMILIAL LONGEVITY
AT MIDDLE AGE
The exceptional ageing process in long-lived individ-
uals and their family members is expressed both at
high and middle age. The survival beneﬁt of the
families from the Leiden Longevity Study (LLS) is
marked by a 30 per cent decreased mortality risk
observed in the survival analysis of three generations,
i.e. the parents of the sibling pairs, their deceased
additional siblings and their offspring [13]. The famil-
ial survival advantage thereby exceeds the increased
lifespan expectancy in the last generations of western
societies due to non-genetic factors. The offspring of
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of diabetes, myocardial infarction, hypertension and
also use less medication for cardiovascular disease
as compared with their partners, with whom they
have shared decades of common environment [15].
Others have observed the same for offspring of cente-
narians who in addition showed also a low prevalence
of cancer [16,17].
We will now discuss the comparison of parameters
in offspring of long-lived individuals and their part-
ners, which may indicate the pathways contributing
to familial longevity. Since a biobank was set up for
the LLS study, parameters can be established in
DNA and RNA isolated from whole blood, serum,
urine, peripheral blood mononuclear cells (PBMCs)
and primary ﬁbroblast strains from skin biopsies. In
addition to more classical parameters, e.g. parameters
of glucose and lipid metabolism, the ongoing pheno-
typing includes lifestyle questionnaires, photographs,
imaging (magnetic resonance imaging of the brain,
X-ray of joints), metabonomics (NMR- and mass-
spec-based) and proteomics.
4. IIS SIGNALLING PARAMETERS IN
LONGEVITY FAMILIES
On the basis of the observations on lifespan extension
in animal models, the most likely favourable biological
features expected to associate with human longevity
would be parameters in IIS signalling and growth,
thyroid metabolism and cellular stress resistance.
Indeed various molecular and cellular phenotypes
were found to mark the altered and probably more
healthy ageing process expressed in the longevity
families. Phenotypes in offspring that change as a
function of age showed patterns usually represented
by younger subjects, as if ageing occurs at a slower
rate. The non-diabetic middle-aged offspring had a
lower prevalence of metabolic syndrome, lower mean
fasting blood glucose and insulin levels, a higher
mean insulin sensitivity and a more favourable glucose
tolerance than their partners. The two groups did not
differ with respect to age, sex distribution, body mass
index (BMI) and lifestyle indices such as the level of
physical activity and smoking behaviour [18,19]. No
differences in serum IGF-1 levels or height were
observed between the total group of offspring and con-
trols. This observation is in contrast with a previous
Ashkenazi Jewish Centenarian Study from which it
was concluded that owing to reduced IGF-1R signal-
ling, IGF-1 levels were increased in female offspring
of centenarians with a concomitant lower height
[20], potentially explained by rare genetic variants in
the IGF-1R gene.
5. LIPID AND THYROID METABOLISM IN
LONGEVITY FAMILIES
Parameters of lipid metabolism (i.e. classical serum
lipids, lipoprotein particle sizes and ApoE levels)
have been associated with calendar age, cardiovascular
health and longevity in human studies. From these
studies, it became clear that serum apolipoprotein/
lipid-based cardiovascular risk factors are different
(and even reversed) for middle-aged and elderly
cohorts.
We and others measured lipoprotein particle size
and analysed the relationship with longevity [21,22].
Recently, we have completed multivariate analyses of
these parameters in the total LLS study population
accounting for correlations with classical lipid par-
ameters. Offspring had larger low-density lipoprotein
(LDL) particle sizes and lower triglyceride levels, indi-
cating that they carry a more beneﬁcial lipid proﬁle.
For comparison, individuals suffering from metabolic
syndrome have the opposite proﬁle. In the multivariate
analysis, we found that, among all lipid parameters,
LDL particle sizes particularly associated with familial
longevity in males, whereas low triglyceride levels
marked female longevity. Thus, lipid metabolism
plays a role in human familial longevity.
The altered glucose and lipid metabolism of longev-
ity families and the preservation of insulin sensitivity
with increasing age resemble the phenotypes of long-
lived dietarily restricted rodents and primates (see
[2] for review). This would predict that not only nutri-
ent-sensing pathways such as IIS but also TOR













































Figure 1. Study design of the Leiden Longevity Study: from LLS phenotypes to biomarkers.
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our genomic studies in the LLS cohort as discussed
below. In addition, our observations may imply that
the hypothalamo-pituitary-thyroid axis is involved in
these features. Indeed, lifespan extension in animal
models associates with low activity of the thyroid hor-
mone axis and in our studies we observed that the
middle-aged offspring have lower serum-free triio-
dothyronine levels compared with their middle-aged
partners, suggesting that a low thyroid hormone
metabolism may contribute to familial longevity at an
early age [23].
A better understanding of pathways that contribute
at middle age to the divergence of healthy and
unhealthy ageing humans may be substantiated by in
depth studies of the cells and tissues of longevity
family members in the context of their genomic
background.
6. GENETIC STUDIES OF HUMAN LONGEVITY
Genetic and genomic studies into longevity have been
performed based on a hypothesis, referred to as a can-
didate gene approach. Alternatively, explorative
genome-wide analyses have been applied in which
genetic variation and gene transcription across the
complete genome are being studied for associations
with longevity and related traits. Genetic studies
into human disease and longevity include candidate
gene approaches, genome-wide association studies
(GWASs) and genome-wide linkage studies.
Such studies in long-lived individuals and their
families may provide more insight into the pathways
that drive the combination of seemingly beneﬁcial
physiological parameters. Longevity may be explained
by the presence, in the genetic make-up of LLS family
members, of alleles protecting against age-related phe-
notypes and diseases that contribute to population
mortality. An alternative explanation may be simply
the absence of alleles promoting such diseases. Now
that the ﬁrst wave of GWASs have generated a catalo-
gue of common genetic variants (single nucleotide
polymorphisms, SNPs) that associate with the major
diseases that contribute to human mortality, it can
be tested whether the disease susceptibility alleles are
absent from the genome of long-lived individuals. We
investigated in nonagenarians from the family-based
Leiden Longevity Study and octogenarians from the
population-based Leiden 85 plus Study the frequency
of a set of alleles currently known to increase the risk of
coronary artery disease, cancer and type-2 diabetes as
identiﬁed by GWASs. Both the nonagenarian siblings
from long-lived families and the sporadic long-lived
individuals appeared to carry the same number of
disease risk alleles as young controls, indicating that
longevity was not easily explained by a remarkable
absence of disease susceptibility alleles. More likely,
therefore, the genome of the long-lived harbours
longevity-promoting alleles. Candidate gene and
genome-wide approaches have been applied to identify
such alleles. The frequency of genetic variants was
typically compared between highly aged cases and
young controls, revealing loci at which genetic variants
may contribute to a higher or lower probability of
survival into old age. So far, this approach has
mainly been applied to study single candidate genes
such as the mammalian orthologues of loci in IIS sig-
nalling pathways that emerged from lifespan extension
studies in animal models. An interesting observation
that needs to be taken into human studies is the fact
that those protective ‘longevity’ genes in animals
indeed exist but do not affect mortality at all ages
[24], not equally in both sexes and associate often
with reduced body size.
The effect of reduced IIS signalling on lifespan
extension in model systems is through changes in
gene expression and especially genes orthologous to
human FOXO transcription factor, HSF-1,ah e a t
shock transcription factor, and NFE2L2 [25], a xeno-
biotic response factor. The initial human candidate
longevity gene studies were dominated by contra-
dictory results [26]. The more consistent evidence
obtained by repeated observation in independent
cohort studies for association to longevity was found
for the APOE locus and, more recently, the FOXO1
and 3 [27–29] and AKT1 loci [30]. The effect size
of the association of the FOXO3 variant appears to
vary with the age of the cases, being most prominent
in centenarians. Other intriguing observations that
need to be replicated but ﬁt observations in humans
at the phenotype level discussed above were made in
the Ashkenazi Jewish Centenarian Study in which a
higher serum thyroid-stimulating hormone level and
TSHR genetic variation marked the centenarian popu-
lation [31]. Recently, an association with longevity was
found for genetic variation in RNA-editing genes [32].
A more complete understanding of the relevance
of genetic variation in inﬂuencing population-wide
mortality and/or population-wide EL may come
closer when cohort studies can be joined in an analysis
of the combined effects of multiple SNPs at age strata
covering the whole lifespan and stratiﬁed by sex.
Previously, a hypothesis-free genome-wide linkage
scan reported evidence for linkage to longevity on
chromosome 4q25 [33]. These results, obtained in
extended longevity families, could not be replicated
in nonagenarian sibling pairs [34] and have to be
further investigated in larger longevity families. More
linkage studies are under way in the GEHA population
[35] and the LLS study.
A number of GWASs applying state-of-the-art
GWAS protocols are also under way. A standard pro-
cedure has been set for GWAS studies in which
accepted levels of statistical signiﬁcance and credible
top hits can only be obtained by a meta-analysis of sev-
eral large cohort studies, to avoid reports on false
positive associations caused by multiple testing and
genotyping errors that occur as a consequence of
high-throughput technology. A GWAS meta-analysis
of four GWASs of survival to age 90 years or older
has been performed, but has not yet reported on
genome-wide signiﬁcant associations [36]. A more
recent GWAS was performed on a study of 1055 cen-
tenarian cases and 1267 controls [37]. Within this
dataset, consisting of a learning set and a small testing
set, a genetic model was generated by which 150 SNPs
described EL and predicted EL in the test set. Since
this study is underpowered and the results were not
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lowing standard procedures for GWAS studies, it is
as yet highly unlikely that the genetic signature predicts
longevity in other studies and that the top hits rep-
resent true new leads for longevity research.
More GWA data are being collected for longevity.
Joint analyses of these studies will be necessary to dis-
entangle this complex trait and to allow for a testing of
the joint associations of genes in a pathway, which is a
more appropriate analysis for a complex trait than
investigating single genes.
7. GENOMIC STUDIES OF HUMAN
AGEING AND LONGEVITY
Genome-wide expression proﬁles have been studied in
brain, lymphocytes, kidney and skeletal muscle tissues
from individuals of different ages [38–42]. Since the
expression of some genes reﬂected the functionality
of the speciﬁc organs they originated from, such
genes may not only mark the chronological ages of
subjects but also their tissues’ biological age. Although
all studies reported gene expression changes to occur
as a function of age, the comparison of offspring of
long-lived subjects and their partners may provide
a step further towards the identiﬁcation of early
and possibly causal contributions to the ageing
process [43].
Gene expression proﬁles in RNA from whole blood
samples were compared between 50 nonagenarians
and 50 controls from the LLS study to investigate
differential gene expression that may arise as a func-
tion of age. Differential expression was observed for
about 7 per cent of the analysed probes. In our
unique study design, we also tested which of these
age-related changes is an early marker of longevity by
comparing gene expression proﬁles of 50 offspring of
the nonagenarians with the controls. Gene expression
differences could be observed in offspring and part-
ners, especially in interaction with age. Among the
limited number of differentially expressed genes, we
observed decreased expression of genes in the
mTOR pathway in the members of long-lived families.
These results, when conﬁrmed, would suggest a role
for TOR signalling in human ageing and lifespan regu-
lation possibly in ways comparable to its role in
lifespan regulation in other species. This would be
supported by the observation that LLS family mem-
bers express DR-like phenotypes (such as preserved
insulin sensitivity). The initial genomic results orig-
inating from micro-array analysis of restricted
sample sizes can now be followed (i) by testing for
differential gene expression by RT–PCR in a much
larger sample of offspring and controls (2500 in
total), (ii) by testing for genetic association of TOR
genes with longevity and longevity-related phenotypes
in the LLS offspring generation (since GWAS data are
available in all subjects of the study), and (iii) by
investigating the pathway in primary ﬁbroblasts of
subjects from the LLS study. By investigating TOR
and IIS signalling in ﬁbroblasts of LLS subjects, func-
tional alterations in speciﬁc proteins may be identiﬁed
which can be tested in the genomic studies of the LLS
cohorts, but also in other cohorts to establish a
relation with human health. In this respect, we are
combining the molecular epidemiological studies in
human longevity with cell biological approaches
(ﬁgure 2). Especially when performing such analyses
in the context of the whole pathway, this approach
may connect to systems biology approaches focused
on the role of the TOR pathway in cancer, diabetes
and ageing.
We reported that ﬁbroblasts from the skin of LLS
study subjects showed increased resistance to cellular
stress, another feature of dietary and genetically
induced lifespan extension in animal models. We
investigated ﬁbroblasts isolated from skin biopsies
obtained from different donor groups: 20 and 90
year olds as well as middle-aged offspring and partners
of the LLS [44]. Fibroblasts were exposed to rotenone
and hyperglycaemia and assessed for senescence-
associated beta-galactosidase (SA-beta-gal) activity,
apoptosis/cell death and growth potential. Stress-
induced increase in SA-beta-gal activity was lower in
ﬁbroblasts from offspring than from partners and
stress-induced apoptosis/cell death was higher in ﬁbro-
blasts obtained from offspring. The observations show
that in vitro cellular responses to stress reﬂect the pro-
pensity for human longevity of the donor. In much the
same way, we investigate whether this propensity is
reﬂected in the TOR and insulin pathways and cellular
phenotypes such as autophagy.
8. THE INFLUENCE OF ENVIRONMENTAL
FACTORS AND EARLY DEVELOPMENT ON
HUMAN AGEING AND LONGEVITY
Genetic studies in humans have thus far not explained
much of the considerable genetic component that was
demonstrated for many physiological health con-
ditions. Our insights may be improved by the study
of rare variants in relevant genes, which has become
feasible by applying novel and affordable deep and
whole-genome sequencing technologies. To fully
understand a complex trait such as longevity showing
moderate heritability, it is also essential that the gene
by environmental interactions be studied. Most of
the human genetic studies have not yet focused on
the analysis of such interactions (which requires large
study samples), and this also requires more knowledge
on the epigenetic regulation of the genome. Epigenetic
marks on the genome regulate chromatin structure and
accessibility of the DNA to the machinery regulating
gene expression. This ‘epigenome’ can serve as a
molecular archive of ongoing and past environmental
conditions. Empirical data to link changes in the
epigenome to disease and ageing are however still
scarce. The best-characterized epigenetic marks are
the methylation of cytosines in cytosine–guanine
(CpG) dinucleotides and the modiﬁcation of histones
that package the DNA. These marks are heritable
during cell division, particularly mitosis, and are
involved in processes that require a stable control of
gene expression, such as the selective gene-silencing
during cell differentiation, parent-of-origin-speciﬁc
silencing (imprinting) and suppressing the transposi-
tion of mobile elements (DNA sequences with the
ability to copy themselves throughout the genome).
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as that proposed by Richard Cutler, increases and
decreases in DNA methylation occur as a function of
age [45,46] and could mark a loss of epigenetic control
and homeostasis [47]. Monozygous twins showed
at ages between 3 and 74 years a divergence of
genome-wide epigenetic and gene expression changes
[48]. Such observations become especially relevant
when they can be linked to the dysregulation of
speciﬁc genes and to phenotypic consequences such
as discordance for metabolic parameters. The study
of one speciﬁc candidate gene for which the relevant
DNA methylation sites are known revealed that vari-
ation in DNA methylation in human populations is
heritable and changed only moderately as a function
of age before 65 years [49]. This study focused on
the well-characterized differentially methylated region
of the imprinted insulin-like growth factor 2 (IGF2)
gene, encoding a key factor in human growth and
development. Following our observation concerning
the IGF2 gene, heritability of DNA methylation has
also been shown in other studies. It will be difﬁcult to
prove how age changes in the epigenome contribute
to human disease if the changes are frequent, stochastic
and age-, tissue- or even cell-speciﬁc.
Numerous epidemiological studies have shown a
link between characteristics of early development and
the occurrence of disease later in life [3]. These obser-
vations form the basis for the Developmental Origins
Hypothesis of Health and Disease (DOHaD), stating
that adverse environmental conditions during speciﬁc
windows of mammalian development can have lasting
effects on metabolic pathways and physiology, thereby
inﬂuencing the susceptibility to disease [50]. By study-
ing speciﬁc methylation sites in a set of candidate
genes involved in metabolism, we have shown in
adult humans that the epigenome harbours molecular
marks of past environmental conditions. We examined
individuals exposed to the Dutch Famine during ges-
tation in the Hunger Winter Families Study. At the
end of World War II, a severe famine affected the wes-
tern part of The Netherlands from November 1944 to
May 1945. The average daily rations, which the auth-
orities distributed during the famine, were less than
700 kcal (cf. normal daily requirements for women
and men are 2000 and 2500 kcal, respectively). Prena-
tal exposure to the famine is associated with various
adverse metabolic and mental phenotypes later in
life, including a higher BMI, elevated plasma lipids,
increased risks of cardiovascular disease and schizo-
phrenia. Many of these associations depended on the
sex of the exposed individual and the timing of the
exposure during gestation. The ﬁrst candidate locus
investigated was again the IGF2 gene. Individuals
who were exposed to famine during early gestation
had a lower IGF2 methylation than controls six dec-
ades after the exposure [51]. Also, methylation at
other loci was associated with prenatal exposure to
famine [52]. Controls in these studies were same-sex
siblings, thus minimizing confounding by sex, early
family environment and the inﬂuence of genetic vari-
ation on DNA methylation. For the IGF2 locus, we
observed small increases in DNA methylation to be
associated with maternal use of folic acid during
periconception [53].
Determinants of developmental set-points that
regulate epigenetic and homeostatic control may be
common denominators for disease, healthy old age
and longevity. The biological effects of variations in
environmental conditions (such as nutrition, antigen
exposure, parental age and lifestyle) should ideally be
investigated systematically across the complete life-
span. Different human cohort studies cover the
different relevant stages in life at which a candidate
pathway can be investigated. The relevant stages that
may inﬂuence morbidity and mortality later in life
include both the prenatal and postnatal development
(early-life programming) and the adult/ageing phase,
determined by the combined consequences of events
occurring during developmental stages and age-related
changes contributing to a decrease in physiological
capacity preceding diagnosed disease. The epigenetic
and genomic changes that may have occurred in
these phases would increase the variation between sub-
jects leading to differences in morbidity, co-morbidity,
mortality and longevity. It may be worthwhile to focus
epigenetic and genomic studies in different life phases
on longevity genes in IIS and TOR signalling,
modelling of existing data from




















Figure 2. Linking molecular epidemiology to cell biology.
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Phil. Trans. R. Soc. B (2011)nutrient-sensing pathways that respond to environ-
mental conditions. Possibly, this level of integrated
research will provide an understanding of the pre-
served insulin sensitivity and DR-like phenotypes
observed in long-lived individuals and their families
and may reveal how to inﬂuence the underlying mech-
anisms for the beneﬁt of elderly individuals in the
general population.
The LLS and epigenetic studies were funded by the
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(SenterNovem; IGE01014 and IGE5007), the Center for
Medical Systems Biology (CMSB), The Netherlands
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research (NGI/NWO; 05040202 and 050-060-810),
the Dutch Heart Foundation (NHS2006B195), The
Netherlands Consortium for Healthy Ageing (050 60810)
and the EU funded Network of Excellence Lifespan
(FP6 036894).
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